Grants and Contributions:

Title:

Cross-linked polyester-based depot systems for sustained drug delivery: determining the relationship between composition, properties and performance

Agreement Number:

CRDPJ

Agreement Value:

$411,627.00

Agreement Date:

Feb 7, 2018 -

Organization:

Natural Sciences and Engineering Research Council of Canada

Location:

Ontario, CA

Reference Number:

GC-2017-Q4-00043

Agreement Type:

Grant

Report Type:

Grants and Contributions

Additional Information:

Grant or Award spanning more than one fiscal year (2017-2018 to 2020-2021).

Recipient's Legal Name:

Allen, Christine (University of Toronto)

Program:

Collaborative Research and Development Grants - Project

Program Purpose:

There are currently more than 20 pharmaceutical products that include implantable, insertable or injectablex000D
drug delivery systems that are formed from the copolymer poly(lactide-co-glycolide) (PLGA) and providex000D
sustained release of drug therapy over time. The sustained drug release that is achieved with a singlex000D
administration, eliminates the need for daily or weekly drug administrations and as a result has a profoundlyx000D
positive impact on a patient's quality of life, patient compliance and leads to significant reductions in healthx000D
care costs. These products are currently used to treat critical medical conditions including diabetes,x000D
endometriosis, prostate cancer and schizophrenia. While PLGA-based systems have provided a deliveryx000D
solution to many drugs, it is clear, a new polymeric delivery system is needed to meet the needs of thex000D
pharmaceutical industry. Given that each drug is unique in terms of its physico-chemical properties and thatx000D
polymer-drug interaction and compatibility are key metrics that influence the performance of polymericx000D
delivery formulations there is no single polymer that can serve as a universal material for formulation of allx000D
drugs. For this reason, Pendant Biosciences (a Canadian company) has patented, and in collaboration with thex000D
Allen laboratory filed an additional provisional patent application, on a flexible polymer platform that includesx000D
recognized building blocks that produce cross-linked biocompatible systems for prolonged delivery of a widex000D
range of drugs. If successful, the proposed research will result in (1) identification of a lead drug-polymerx000D
product for development by Pendant Biosciences; (2) a 'tool-box' of biocompatible polymer materials tox000D
facilitate drug-delivery research in academic and industrial settings and (3) increased scientific awareness ofx000D
the physical and chemical metrics responsible for the performance of a drug-polymer combination product.